Miguel Regueiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6071802/publications.pdf

Version: 2024-02-01

103 papers 4,467 citations

34 h-index

117571

64 g-index

104 all docs

104 docs citations

104 times ranked 4380 citing authors

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection. Gastroenterology, 2009, 136, 441-450.e1. | 0.6 | 561 |
| 2 | The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Diseases, Colitis Foundation. Inflammatory Bowel Diseases, 2020, 26, 1-10. | 0.9 | 274 |
| 3 | Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton Placement. Inflammatory Bowel Diseases, 2003, 9, 98-103. | 0.9 | 256 |
| 4 | Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology, 2016, 150, 1568-1578. | 0.6 | 251 |
| 5 | Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. American Journal of Gastroenterology, 2003, 98, 1821-1826. | 0.2 | 209 |
| 6 | Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. American Journal of Gastroenterology, 2016, 111, 712-719. | 0.2 | 156 |
| 7 | Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World Journal of Gastroenterology, 2020, 26, 2323-2331. | 1.4 | 130 |
| 8 | Crohn $\hat{E}\frac{1}{4}$ s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflammatory Bowel Diseases, 2011, 17, 118-126. | 0.9 | 125 |
| 9 | Infliximab dose intensification in Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 1093-1099. | 0.9 | 119 |
| 10 | Postoperative Therapy With Infliximab Prevents Long-term Crohn's Disease Recurrence. Clinical Gastroenterology and Hepatology, 2014, 12, 1494-1502.e1. | 2.4 | 118 |
| 11 | American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After SurgicalÂResection. Gastroenterology, 2017, 152, 277-295.e3. | 0.6 | 110 |
| 12 | A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology, 2016, 151, 724-732. | 0.6 | 109 |
| 13 | A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). American Journal of Gastroenterology, 2019, 114, 472-482. | 0.2 | 108 |
| 14 | Etiology and Treatment of Pain and Psychosocial Issues inÂPatients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 430-439.e4. | 0.6 | 104 |
| 15 | Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflammatory Bowel Diseases, 2006, 12, 979-994. | 0.9 | 97 |
| 16 | Perioperative and Postoperative Management of Patients With Crohn's Disease and Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1356-1366. | 2.4 | 65 |
| 17 | Infliximab for Hospitalized Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2006, 40, 476-481. | 1.1 | 64 |
| 18 | Reduced Unplanned Care and Disease Activity and Increased Quality of Life After Patient Enrollment in an Inflammatory Bowel Disease Medical Home. Clinical Gastroenterology and Hepatology, 2018, 16, 1777-1785. | 2.4 | 63 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1760-1766. | 2.4 | 62 |
| 20 | Association Between Telephone Activity and Features ofÂPatientsÂWith Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 986-994.e1. | 2.4 | 60 |
| 21 | Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement. Inflammatory Bowel Diseases, 2006, 12, 972-978. | 0.9 | 59 |
| 22 | TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemporary Clinical Trials, 2015, 42, 132-144. | 0.8 | 58 |
| 23 | Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. Current Gastroenterology Reports, 2019, 21, 31. | 1.1 | 55 |
| 24 | Innovation in Inflammatory Bowel Disease Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease. Gastroenterology, 2020, 159, 805-808.e1. | 0.6 | 54 |
| 25 | Cigarette Smoking and Age at Diagnosis of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2005, 11, 42-47. | 0.9 | 52 |
| 26 | Managing Risks with Biologics. Current Gastroenterology Reports, 2019, 21, 1. | 1.1 | 50 |
| 27 | Management and prevention of postoperative Crohn \hat{E} 1/4s disease. Inflammatory Bowel Diseases, 2009, 15, 1583-1590. | 0.9 | 46 |
| 28 | Constructing an Inflammatory Bowel Disease Patient–Centered Medical Home. Clinical Gastroenterology and Hepatology, 2017, 15, 1148-1153.e4. | 2.4 | 46 |
| 29 | Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2510-2517.e5. | 2.4 | 46 |
| 30 | Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn's Disease. Digestive Diseases and Sciences, 2011, 56, 3610-3615. | 1.1 | 42 |
| 31 | Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2016, 61, 865-871. | 1.1 | 42 |
| 32 | Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. American Journal of Gastroenterology, 2017, 112, 1849-1858. | 0.2 | 41 |
| 33 | Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn's Disease Patients Independent of Inflammation Recurrence. American Journal of Gastroenterology, 2018, 113, 576-583. | 0.2 | 40 |
| 34 | Lower Rates of Colorectal Cancer in Patients With Inflammatory Bowel Disease Using Anti-TNF Therapy. Inflammatory Bowel Diseases, 2021, 27, 1052-1060. | 0.9 | 37 |
| 35 | Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflammatory Bowel Diseases, 2011, 17, 1008-1014. | 0.9 | 36 |
| 36 | A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflammatory Bowel Diseases, 2019, 25, 831-842. | 0.9 | 35 |

3

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e974-e983. | 2.4 | 34 |
| 38 | The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Diseases, 2018, 24, 1380-1388. | 0.9 | 31 |
| 39 | Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. Digestive Diseases and Sciences, 2016, 61, 3236-3245. | 1.1 | 28 |
| 40 | Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn's Disease, Based on 6-Year Follow-Up. Clinical Gastroenterology and Hepatology, 2018, 16, 900-907.e1. | 2.4 | 26 |
| 41 | Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy. Digestive Diseases and Sciences, 2020, 65, 96-103. | 1.1 | 26 |
| 42 | Gastrointestinal manifestations of COVID-19. Cleveland Clinic Journal of Medicine, 2021, , . | 0.6 | 26 |
| 43 | Safety and Efficacy of Bariatric Surgery in Inflammatory Bowel Disease Patients: a Systematic Review and Meta-analysis. Obesity Surgery, 2020, 30, 3872-3883. | 1.1 | 25 |
| 44 | Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?. Inflammatory Intestinal Diseases, 2022, 7, 50-58. | 0.8 | 24 |
| 45 | Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1268-1275. | 0.9 | 23 |
| 46 | Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients. Digestive Diseases and Sciences, 2022, 67, 3138-3147. | 1.1 | 23 |
| 47 | The role of endoscopy in the evaluation of fistulizing Crohn's disease. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 621-633. | 0.6 | 21 |
| 48 | A Practical Approach to Preventing Postoperative Recurrence in Crohn's Disease. Current Gastroenterology Reports, 2016, 18, 25. | 1.1 | 20 |
| 49 | International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2020, 14, S780-S784. | 0.6 | 20 |
| 50 | Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Inflammatory Bowel Diseases, 2021, 27, 1394-1408. | 0.9 | 20 |
| 51 | Making a Medical Home for IBD Patients. Current Gastroenterology Reports, 2017, 19, 20. | 1.1 | 18 |
| 52 | Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 Year. Inflammatory Bowel Diseases, 2018, 24, 2191-2197. | 0.9 | 18 |
| 53 | Underwater versus conventional endoscopic mucosal resection for colorectal lesions: a systematic review and meta-analysis. Endoscopy International Open, 2020, 08, E1884-E1894. | 0.9 | 18 |
| 54 | Mesenteric Excision and Exclusion for Ileocolic Crohn's Disease: Feasibility and Safety of an Innovative, Combined Surgical Approach With Extended Mesenteric Excision and Kono-S Anastomosis. Diseases of the Colon and Rectum, 2022, 65, e5-e13. | 0.7 | 16 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study. Clinical Gastroenterology and Hepatology, 2022, 20, 96-104. | 2.4 | 15 |
| 56 | TELEmedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Does Not Improve Depressive Symptoms or General Quality of Life Compared With Standard Care at Tertiary Referral Centers. Crohn's & Colitis 360, 2020, 2, otaa002. | 0.5 | 15 |
| 57 | Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn's Disease. Journal of Crohn's and Colitis, 2021, 15, 24-34. | 0.6 | 15 |
| 58 | Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. Clinical and Translational Gastroenterology, 2016, 7, e181. | 1.3 | 14 |
| 59 | Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis ofÂData From Clinical Trials. Clinical Gastroenterology and Hepatology, 2016, 14, 1753-1762. | 2.4 | 14 |
| 60 | The Inflammatory Bowel Disease Medical Home: From Patients to Populations. Inflammatory Bowel Diseases, 2019, 25, 1881-1885. | 0.9 | 14 |
| 61 | Value-Based Health Care in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 958-968. | 0.9 | 13 |
| 62 | Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences, 2018, 63, 2729-2739. | 1.1 | 11 |
| 63 | lleocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance. Inflammatory Bowel Diseases, 2022, 28, 289-298. | 0.9 | 10 |
| 64 | Correlation of anemia status with worsening bowel damage as measured by Lémann Index in patients with Crohn's disease. Digestive and Liver Disease, 2016, 48, 626-631. | 0.4 | 9 |
| 65 | Age Modifies the Association Between Depressive Symptoms and Adherence to Self-Testing With Telemedicine in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2648-2654. | 0.9 | 8 |
| 66 | Risks, time trends, and mortality of colonoscopyâ€induced perforation in hospitalized patients. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1381-1386. | 1.4 | 8 |
| 67 | Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence. Journal of Crohn's and Colitis, 2022, 16, 1696-1705. | 0.6 | 8 |
| 68 | Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies. Journal of Gastrointestinal Surgery, 2016, 20, 1415-1420. | 0.9 | 7 |
| 69 | Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes?. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 487-514. | 0.6 | 7 |
| 70 | Special Considerations for Colorectal Surgery in the Elderly IBD Patient. Current Treatment Options in Gastroenterology, 2019, 17, 449-456. | 0.3 | 7 |
| 71 | Hepatic manifestations of COVID-19. Cleveland Clinic Journal of Medicine, 2020, , . | 0.6 | 7 |
| 72 | Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease. Inflammatory Bowel Diseases, 2021, , . | 0.9 | 6 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Three-Dimensional Nanoscale Nuclear Architecture Mapping of Rectal Biopsies Detects Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Cancer Prevention Research, 2019, 12, 527-538. | 0.7 | 5 |
| 74 | Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn's disease: a systematic review and meta-analysis. Annals of Gastroenterology, 2021, 34, 691-698. | 0.4 | 5 |
| 75 | Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflammatory Bowel Diseases, 2022, 28, 1321-1331. | 0.9 | 5 |
| 76 | Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. Inflammatory Bowel Diseases, 2023, 29, 51-61. | 0.9 | 5 |
| 77 | Knowledge Gaps in the Management of Postoperative Crohn's Disease: A US National Survey. Digestive Diseases and Sciences, 2018, 63, 53-60. | 1.1 | 4 |
| 78 | COVID-19 in patients with IBD and pancreatic obiliary disorders. Cleveland Clinic Journal of Medicine, 2020, , . | 0.6 | 4 |
| 79 | Rate and risk factors of postoperative endoscopic recurrence of moderate- to high-risk Crohn's disease patients - A real-world experience from a Middle Eastern cohort. Saudi Journal of Gastroenterology, 2022, . | 0.5 | 4 |
| 80 | Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. Crohn's & Colitis 360, 2019, 1, . | 0.5 | 3 |
| 81 | Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 3563-3569. | 1.1 | 3 |
| 82 | Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, 1481-1490. | 0.6 | 3 |
| 83 | Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?. Diseases of the Colon and Rectum, 2021, 64, 1106-1111. | 0.7 | 3 |
| 84 | Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. Crohn's & Colitis 360, 2021, 3, . | 0.5 | 3 |
| 85 | The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients with Inflammatory Bowel Disease. Diseases of the Colon and Rectum, 2021, Publish Ahead of Print, 1364-1373. | 0.7 | 3 |
| 86 | Small Bowel Crohn's Disease Recurrence is Common After Total Proctocolectomy for Crohn's Colitis. Diseases of the Colon and Rectum, 2022, 65, 390-398. | 0.7 | 3 |
| 87 | Inflammatory Bowel Disease Patients' Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis. Crohn's & Colitis 360, 2021, 3, . | 0.5 | 3 |
| 88 | Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis: preliminary phase IB/IIA study. British Journal of Surgery, 2022, 109, 653-655. | 0.1 | 3 |
| 89 | Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterology, 2022, 22, 71. | 0.8 | 3 |
| 90 | Venous Thromboembolism in Admitted Patients with Inflammatory Bowel Disease: An Enterprise-Wide Experience of 86,000 Hospital Encounters. Diseases of the Colon and Rectum, 2022, Publish Ahead of Print, . | 0.7 | 3 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | The old versus the new: which do you keep in postoperative Crohn's disease?. Intestinal Research, 2018, 16, 319. | 1.0 | 2 |
| 92 | Listening to the Patient: Improving the Design and Conduct of Clinical Trials in Inflammatory Bowel Diseases. Crohn's & Colitis 360, 2020, 2, . | 0.5 | 2 |
| 93 | Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflammatory Bowel Diseases, 2020, 26, 1291-1305. | 0.9 | 2 |
| 94 | Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?. Inflammatory Bowel Diseases, 2021, 27, 291-294. | 0.9 | 2 |
| 95 | Trends and Outcomes of Acute Diverticulitis in Inflammatory Bowel Disease: A Propensity-matched National Study. Inflammatory Bowel Diseases, 2022, 28, 48-53. | 0.9 | 2 |
| 96 | Anorectal Strictures in Complex Perianal CD: How to Approach?. Clinics in Colon and Rectal Surgery, 2022, 35, 044-050. | 0.5 | 2 |
| 97 | Intravenous Cyclosporine in Severe Ulcerative Colitis: How Low Can You Go?. Inflammatory Bowel Diseases, 2004, 10, 170. | 0.9 | 1 |
| 98 | Response Friedman and Sparrow re: Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2011 [Epub ahead of print] Inflammatory Bowel Diseases, 2011, 17, E163. | 0.9 | 1 |
| 99 | Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 1407. | 2.4 | 1 |
| 100 | Preface. Gastroenterology Clinics of North America, 2009, 38, ix-x. | 1.0 | 0 |
| 101 | Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 1764-1765. | 2.4 | 0 |
| 102 | Editorial for Nancy Stoll's Article. Crohn's & Colitis 360, 2019, 1, . | 0.5 | 0 |
| 103 | First or Second Biologic in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, 740-746. | 1.1 | O |